Feasibility of Treating Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma With Zanubrutinib in Combination With the BCL2 Inhibitor, Sonrotoclax, Focusing on Access for Underrepresented Ethnic/Racial Minorities

This phase I trial tests zanubrutinib in combination with sonrotoclax for treating underrepresented ethnic and racial minorities with B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Many racial and ethnic minorities face additional treatment challenges which may lead to poorer outcomes, however, there are fewer racial and ethnic minorities participating in clinical trials. Zanubrutinib, a type of tyrosine kinase inhibitor, blocks a protein called Bruton tyrosine kinase (BTK), which may help keep cancer cells from growing. Sonrotoclax works by blocking a protein called B-cell lymphoma-2 (Bcl-2). This protein helps certain types of blood cancer cells to survive and grow. When sonrotoclax blocks Bcl-2, it slows down or stops the growth of cancer cells and causes them to die. Zanubrutinib and sonrotoclax have been shown to be an effective treatment for B-cell cancers. Giving zanubrutinib in combination with sonrotoclax may be effective in treating ethnic and racial minorities with relapsed or refractory B-cell non-Hodgkin lymphoma.

开始日期2026-02-07

申办/合作机构

City of Hope National Medical Center

[+1]

NCT07141511

/ Not yet recruiting临床1期

A Phase 1, Single-dose, Open-label, Randomized, Crossover Study in Healthy Adult Participants to Evaluate Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332)

The purpose of this study is to evaluate the relative bioavailability of a fixed-dose combination tablet containing zanubrutinib and sonrotoclax (BG-71332) compared to a zanubrutinib capsule and sonrotoclax tablet administered simultaneously and the effect of food on how the body processes the fixed-dose combination tablet.

开始日期2025-09-01

申办/合作机构

BeOne Medicines Ltd.

NCT06854003

/ Not yet recruiting临床2期IIT

A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

This study aims to evaluate the efficacy and safety of an induction regimen combining Bendamustine, Rituximab, Cytarabine (AraC), and Zanubrutinib (BRAZAN), followed by maintenance therapy with Zanubrutinib and Rituximab with or without Sonrotoclax in participants with Mantle Cell Lymphoma (MCL).
The names of the study drugs involved in this study are:
* bendamustine (a type of alkylating agent)
* rituximab (a type of monoclonal antibody)
* cytarabine (a type of antineoplastic)
* zanubrutinib (a type of kinase inhibitor)
* sonrotoclax (a type of BCL2 inhibitor)

开始日期2025-08-01

申办/合作机构

Dana-Farber Cancer Institute, Inc.

[+1]

100 项与索托克拉相关的临床结果

登录后查看更多信息

100 项与索托克拉相关的转化医学

登录后查看更多信息

100 项与索托克拉相关的专利（医药）

登录后查看更多信息

项与索托克拉相关的文献（医药）

2025-08-01·CANCER LETTERS

Sonrotoclax (BGB-11417) synergistically amplifies the radiotherapy-elicited anti-tumor immune response

Article

作者: Liu, Xu ; Yu, Jinming ; Ma, Mengmeng ; Chen, Dawei ; Wu, Meng ; Tian, Chen ; Zhang, Zengfu ; Yuan, Jupeng

Escape from apoptosis is one of the main hallmarks of cancer. The imbalance of BCL-2 family members is a key factor leading to radiotherapy resistance. Targeting BCL-2 can overcome radiotherapy resistance by promoting apoptosis. Nevertheless, the function of BCL-2 in regulating the tumor immune microenvironment (TIME) is still not well understood. Herein, we discovered that the specific BCL-2 inhibitor sonrotoclax (BGB-11417) boosted the effectiveness of radiotherapy in an immune-mediated manner. Using flow cytometry, we found that sonrotoclax combined with radiotherapy polarized tumor-associated macrophages (TAMs) toward the M1-type and promoted the infiltration of Gzmb⁺ CD8⁺ T cells into the tumor. Mechanistically, we demonstrated that the combination of sonrotoclax and radiotherapy induced immunogenic ferroptosis of cancer cells by inhibiting GPX4 expression, released tumor-associated damage-associated molecular patterns (DAMPs) and subsequently activated the NF-κB pathway in TAMs. Moreover, the combination therapy also led to aberrant cytosolic DNA abundance and activated the cGAS-STING pathway in cancer cells, leading to the release of type I interferons and enhanced activation of CD8⁺ T cells. Meanwhile, the activation of cGAS-STING pathway also led to the upregulation of PD-L1 expression. Further combination of sonrotoclax and radiotherapy plus anti-PD-L1 exerted the most significant anti-tumor effects. Overall, our study indicated that sonrotoclax enhanced the anti-tumor immune response of radiotherapy through non-apoptotic roles of BCL-2, and shed light on the further clinical evaluation of the triple combination therapy of sonrotoclax, radiotherapy and immunotherapy.

2025-07-01·HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Triplet Therapies in Chronic Lymphocytic Leukemia

Review

作者: Soumerai, Jacob D ; Davids, Matthew S

Triplet therapy regimens, which we define as the combination of a BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib), BCL2 inhibitor (venetoclax or sonrotoclax), and a CD20 antibody (obinutuzumab), have been developed in chronic lymphocytic leukemia (CLL). Herein, we comprehensively review the available clinical data for triplet regimens in treatment-naïve CLL, including an evidence-based discussion of the role of TP53 aberrancy in patients receiving triplet therapies, and of retreatment options after frontline triplet therapy. We also review ongoing trials with potential to further define the role of triplet therapies in treatment-naïve CLL.

2025-06-01·HEMATOLOGICAL ONCOLOGY

Diagnosis and Management of Waldenstrom's Macroglobulinemia.

Review

作者: Treon, Steven P ; Sarosiek, Shayna ; Castillo, Jorge J

Waldenström macroglobulinemia (WM) is an IgM secreting lymphoplasmacytic lymphoma. Mutations in MYD88 (95%-97%) and CXCR4 (30%-40%) are common in patients with WM. TP53 is also altered in up to 30% of WM patients, particularly those previously treated. Mutated MYD88 triggers the expression and activation of HCK that drives multiple pro-survival signaling cascades, including BTK. There are over 40 CXCR4 mutation types in WM. WM patients bearing nonsense CXCR4 variants can present with symptomatic hyperviscosity and show greater resistance to covalent BTK inhibitors (cBTK-i). The cBTK-i zanubrutinib shows greater response activity and/or improved progression-free survival in WM patients with wild-type MYD88, mutated CXCR4, or altered TP53. New or emerging options for patients progressing on c-BTKi include pirtobrutinib, BGB-16673, venetoclax, and sonrotoclax. Combinations of BTK inhibitors with chemoimmunotherapy and BCL2 antagonists have advanced. Algorithms for patients with treatment-naïve and previously treated WM based on genomics, disease characteristics, and co-morbidities are discussed.

223

项与索托克拉相关的新闻（医药）

2025-08-26

·氨基观察

映恩生物上半年调整后利润1.46亿元，现金37.47亿元；礼来口服GLP-1一项3期临床成功

氨基观察-创新药组原创出品作者 | 黄恺多家明星药企，带来亮眼成绩单。 8月26日，映恩生物公告，上半年总营收12.29亿元，调整后利润1.46亿元，现金总额达到37.47亿元。康诺亚也是在同一天宣布，上半年营收4.99亿元，同比暴增812%，其中包括合作收入3.29亿元。研发支出3.60亿元，同比增长9%。礼来口服GLP-1一项3期临床成功。 8月26日，礼来公布了其在研GLP-1受体激动剂orforglipron的3期临床试验ATTAIN-2的积极顶线结果。该研究针对合并2型糖尿病的肥胖或超重成人患者。在ATTAIN-2研究中，orforglipron的3个剂量组均达到了主要终点和所有关键次要终点，在72周时实现了显著的体重下降、具有临床意义的糖化血红蛋白（A1C）降低，及心血管风险因素的改善。在主要终点方面，每日一次且在不受食物或饮水限制的前提下，orforglipron 36mg组平均体重下降达10.5%（10.4kg），而安慰剂组为2.2%（2.3kg）。在过去的一天里，国内外医药市场还有哪些热点值得关注？让氨基君带你一探究竟。 / 01 / 市场速递 1）9.5亿美元出海，百济改写BD交易逻辑 8月25日，百济神州宣布与Royalty Pharma签订特许权使用费购买协议。后者支付8.85亿美元首付款，获得百济神州旗下塔拉妥单抗（Imdelltra，tarlatamab）在中国以外地区销售的特许权使用费权益。根据协议条款，百济神州有权在12个月内出售剩余的收取特许权使用费的权利，由此最高可获得6500万美元的额外付款。百济神州还将根据特许权使用费所占比例，享有该产品年销售额超15亿美元的部分收入。 2）汇宇制药拟与同源康签署全国总代理协议 8月26日，汇宇制药公告，全资子公司汇辰昕拟与同源康签署《关于同源康“TY-9591”产品的全国总代理协议》，同源康同意将其“TY-9591”产品的全国总代理权授权给汇辰昕，里程碑首付款为15000万元人民币。“TY-9591”产品是由同源康自主研发的可口服、不可逆的第三代EGFR（表皮生长因子受体）抑制剂。 / 02 / 资本信息 1）君实生物上半年营业收入同比增长48.64% 8月26日，君实生物公告，2025年上半年公司营业收入为11.68亿元，同比增长48.64%；归属于上市公司股东的净亏损4.13亿元，上年同期净亏损6.45亿元。 2）复星医药上半年净利润同比增长38.96% 8月26日，复星医药公告，2025年上半年营业收入195.14亿元，净利润17.02亿元，同比增长38.96%。 3）映恩生物上半年调整后利润1.46亿元，现金37.47亿元 8月26日，映恩生物公告，上半年总营收12.29亿元，调整后利润1.46亿元，现金总额达到37.47亿元。 4）康诺亚上半年营收暴增812% 8 月 26 日，康诺亚发布2025上半年业绩公告，营收4.99亿元，同比暴增812%，其中包括合作收入3.29亿元。研发支出3.60亿元，同比增长9%。 / 03 / 医药动态 1）康诺亚CM336注射液获临床许可 8月26日，据CDE官网，康诺亚CM336注射液获临床许可，拟用于自身免疫性血细胞减少症。 2）百济神州Sonrotoclax薄膜包衣片获临床许可 8月26日，据CDE官网，百济神州Sonrotoclax薄膜包衣片获临床许可，拟联合抗CD20抗体治疗复发和/或难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。 / 04 / 海外药闻 1）礼来口服GLP-1RA orforglipron肥胖合并2型糖尿病的3期临床研究成功 8月26日，礼来公布了其在研GLP-1受体激动剂orforglipron的3期临床试验ATTAIN-2的积极顶线结果。该研究针对合并2型糖尿病的肥胖或超重成人患者。在ATTAIN-2研究中，orforglipron的3个剂量组均达到了主要终点和所有关键次要终点，在72周时实现了显著的体重下降、具有临床意义的糖化血红蛋白（A1C）降低，及心血管风险因素的改善。在主要终点方面，每日一次且在不受食物或饮水限制的前提下，orforglipron 36mg组平均体重下降达10.5%（10.4kg），而安慰剂组为2.2%（2.3kg）。 2）诺华押注神经退行性疾病新疗法 8 月 26 日，BioArctic AB (publ) 宣布，已与诺华达成一项期权、合作及许可协议。该协议将 BioArctic 专有的 BrainTransporter 技术与神经退行性疾病领域一个未公开的靶点相结合，开发一种潜在的新疗法。作为初步研究合作的一部分，BioArctic 将获得 3000 万美元的预付款。 PS：欢迎扫描下方二维码，添加氨基君微信号交流。

财报临床3期引进/卖出临床1期

2025-08-25

·BioPharmaDive

Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales

Dive Brief:Royalty Pharma has grabbed rights to a share in revenue from lung cancer drug Imdelltra, announcing Monday it will pay $885 million upfront for BeOne Medicines royalties paid by partner Amgen for sales outside China. BeOne, formerly known as BeiGene, has rights to Imdelltra revenue because of a $2.7 billion collaboration deal it struck with Amgen in 2019.Per deal terms, BeOne has the option to sell another chunk of Imdelltra royalties in the next year for $65 million, bringing the deal total to around $950 million. Royalty said the initial royalty stream amounted to approximately 7% of worldwide net sales.Launched in 2024 for small cell lung cancer, Imdelltra earned sales of $215 million through the first six months of 2025, most of it in the U.S. under an accelerated approval from the Food and Drug Administration. Amgen recently reported data from a clinical trial showing the drug extends survival compared with chemotherapy, which should secure its place on the market.Dive InsightBeOne is now well established as a commercial drugmaker, recording total sales of $2.4 billion through the first six months of the year from drugs it developed as well as some of Amgens products in China. However, it also has significant expenses, burning about $2 billion over the same time about half on research and development of its own drugs like Brukinsa and sonrotoclax.That profit picture for the first half looks like it will be sustained for the full year, as BeOnes executives forecast positive operating income and cash flow even before this deal was announced. The deal will only build on that momentum, executives said Monday.A strong balance sheet is a hallmark of the most successful companies in our industry, and this transaction provides increased operational and strategic flexibility as we continue to execute our business strategy for the long term, said CFO Aaron Rosenberg, in a statement.A so-called bispecific antibody, Imdelltra triggers an immune response to cells expressing a protein called DLL-3, common among tumor cells in small cell cancer, a hard-to-treat disease that until recently has had few innovative treatments. While Merck & Co.s immunotherapy Keytruda and Bristol Myers Squibbs Opdivo have gained approval for small cell lung cancer, they were withdrawn when confirmatory data didnt support their use. Roches Tecentriq can be used in certain patients, however.Imdelltra is reshaping the treatment paradigm for patients with small cell lung cancer, a highly aggressive disease with few treatment options, said Pablo Legorreta, Royaltys CEO, in a statement. Todays transaction is consistent with our strategy of acquiring royalties on highly transformative products in life sciences.Royalty Pharma has been active in buying revenue streams recently, striking deals with Biogen, Cytokinetics, Sanofi and Agios. '

免疫疗法上市批准引进/卖出加速审批

2025-08-24

·汇聚南药

创新药龙头，成功上岸

作者｜momo 凭借核心产品泽布替尼在全球市场的强劲表现，百济神州在2025年上半年交出了一份亮眼的答卷，成功“上岸”国际主流市场。 01 重磅炸弹持续增长 8月6日，百济神州发布了2025年Q2及H1业绩报告，数据十分亮眼。财报显示，公司不仅成功实现持续性盈利，更在核心产品驱动下展现出强劲的增长动能。2025年Q2，百济神州实现GAAP净利润9400万美元，相较去年同期大幅扭亏（增加2.15亿美元），并产生2.20亿美元自由现金流。上半年GAAP净利润达9559万美元，同样实现显著逆转（去年同期亏损3.72亿美元）。支撑这一盈利转折的关键因素，正是其重磅产品泽布替尼的持续高速放量以及替雷利珠单抗的稳健增长。诚然，泽布替尼无疑是最耀眼的明星。2025年Q1其在美国销售额约5.9亿美元，同比增长61.9%，首次超越伊布替尼和阿卡替尼，占据BTK抑制剂市场头把交椅，成为国货之光。在头对头试验中，在慢性淋巴细胞白血病（CLL）等适应症中，泽布替尼的客观缓解率（ORR）和无进展生存期（PFS）均显著优于第一代BTK抑制剂伊布替尼。2025年Q2，其全球销售额飙升至9.5亿美元，同比增长49%，显著超越公司产品收入整体增速（42%）。上半年累计销售额高达17.4亿美元，奠定了其在全球BTK抑制剂市场的领先地位。图1.泽布替尼是美国收入领先、增长最快的品牌其中，第二季度美国市场贡献6.84亿美元，同比增长43%，持续保持新患者市场份额领先。其临床确立的BIC地位以及最广泛的获批适应症是驱动美国市场持续渗透的核心动力（图1）；另外，欧洲市场亦展现出巨大潜力，第二季度销售额达1.5亿美元，同比飙升85%，成为增长最快的区域，充分验证了百济国际化战略的有效性。值得注意的是，泽布替尼在第二季度新增或扩大了5个市场的报销覆盖范围，新剂型薄膜包衣片获美国FDA批准及欧洲积极意见，进一步提升了用药便利性和市场潜力。其全球销售占比提升及生产效率优化，直接推动了公司GAAP毛利率由上年同期的85.0%提升至87.4%。与此同时，作为另一核心产品，替雷利珠单抗在第二季度也有稳健表现，实现销售额1.94亿美元，同比增长22%，环比增长13.4%。其增长动力主要来自现有市场的持续渗透。值得关注的是，百济神州正积极推进替雷利珠单抗的海外商业化进程，有望成为其未来增长的重要引擎。 02 国内药企出海标杆全球医药市场持续扩张，预计到2030年将突破2万亿美元，其中中国市场虽位居全球第二，但在创新药支付支持方面仍面临挑战。与此同时，发达国家凭借其支付体系优势，为创新药提供了广阔的定价空间，同一款国产创新药在海外市场的定价往往远高于本土。因此，“出海”成为中国药企突破国内增长瓶颈、提升全球竞争力与商业价值的必选项。在多元化的出海路径中，自主出海以其对企业海外研发与商业化主导权的保障，成为最具价值但也最考验企业综合实力的模式。它要求企业直面国际监管环境的复杂性、承担高昂的初期投入与漫长的回报周期。在这一领域，百济神州树立了标杆地位（图2）。其核心产品泽布替尼于2019年获得美国FDA批准，成为首个成功打入美国市场的国产自研创新药，实现了国产新药自主出海“零的突破”。当然，泽布替尼也不负众望，2023年便成长为销售额突破十亿美元的“重磅炸弹”。图2.自主出海的国产创新药此外，百济神州在另一核心产品替雷利珠单抗的出海历程中展现出非凡的战略韧性与灵活的商业智慧。虽然曾借助诺华的国际化渠道推进，却因疫情核查受阻及合作伙伴战略调整而波折重重。面对挑战，百济神州果断收回全球权益，并凭借自身实力最终推动替雷利珠单抗在2024年成功登陆美国，成为首个获FDA批准用于食管鳞癌的中国PD-1药物。为应对激烈的市场竞争，百济神州则选择主动降价。公司宣称，替雷利珠单抗将比美国市场上的疗法定价低10%。尽管以比美国现有疗法低10%的价格销售，其在中美市场的价差仍高达20倍以上。这种基于对全球支付差异深刻洞察的务实策略，既争取了市场主动权，又确保了在海外成熟市场销售的商业可行性。 03 祭出后手棋在创新药研发的激烈角逐中，百济神州在巩固血液肿瘤优势的同时，向实体瘤领域强势推进，祭出一系列关键“后手棋”（图3）。其中，BCL2抑制剂索托克拉（Sotonoclax）的快速推进是其巩固血液瘤优势的关键落子。相较于当前全球唯一上市的BCL2抑制剂维奈克拉（Venetoclax），索托克拉在效价、选择性、PK 性能等方面均具有同类最佳潜力。索托克拉单药治疗复发/难治性（R/R）CLL/SLL和R/R MCL已在中国基于II期数据申报上市；其联合泽布替尼用于初治CLL/SLL的头对头III期研究（对比维奈克拉+奥妥珠单抗）已于2025年2月完成入组，是全球首个旨在证明PFS优效性的此类III期试验，数据读出有望重塑一线治疗格局。其在MCL、华氏巨球蛋白血症（WM）、多发性骨髓瘤（MM）、急性髓系白血病（AML）等适应症的拓展将进一步释放其“大品种”潜力。图3.百济神州在研管线此外，为了针对经治患者尤其是对现有BTKi和BCL2i产生耐药的后线需求，百济布局了BTK-CDAC技术。其代表产品BGB-16673 在既往接受过多线治疗的 R/R CLL 患者中观察到显著缓解，针对共价 BTKi+BCL2i 经治患者、共价 BT Ki+非共价 BTKi+BCL2i 经治患者的 ORR 分别达 90.5%、75%。公司已启动针对既往接受过共价 BTK 抑制剂治疗的 R/R CLL/SLL 患者的全球III期研究，头对头匹妥布替尼。预计2025年下半年完成首例入组。与此同时，百济神州在实体瘤领域构建了以CDK4抑制剂、B7-H4 ADC和KRAS系列为核心的强大管线，2025-2026年多项关键概念验证（POC）数据读出将迎来价值重估拐点。 BGB-43395作为高选择性CDK4抑制剂，旨在避免抑制CDK6带来的脱靶毒性。其在HR+乳腺癌一线治疗中已追平全球首款CDK4抑制剂Atirmociclib（辉瑞）的研发进度，并在有效剂量下展现出更优的安全性。公司计划启动一线及二线治疗的III期研究，二线研究最快2025年第四季度启动，有望引领乳腺癌靶向治疗升级。与映恩生物合作的BG-C9074靶向在乳腺癌、子宫内膜癌、卵巢癌中高表达而在正常组织中有限的B7-H4蛋白。其临床前数据亮眼，具备剂量依赖性体内药效、良好内化能力和旁观者杀伤效应，具有“同类首创”潜力。公司预计2025年第三季度启动肿瘤特异性扩展队列入组，为表达B7-H4的难治性肿瘤患者带来新希望。针对KRAS突变的异质性和耐药挑战，百济布局了panKRAS抑制剂BGB-53038及KRAS CDAC与RAS(ON)抑制剂，BGB-53038覆盖多种KRAS突变亚型，且不影响野生型KRAS/HRAS/NRAS，相比竞品panRAS抑制剂（如RMC-6236）有望提供更佳治疗窗口，潜力成为“同类最佳”，预计2025年下半年完成POC。结语百济神州的成功“上岸”，撕开了发达国家市场高墙的一道口子，证明中国创新药不仅能参与全球竞争，更能定义赛道标准。参考资料 [1]https://ir-api.eqs.com/media/document/1912ebd9-b846-45b5-a8b7-a1ff3a3ff438/assets/BeOne_Q2_2025_Earnings_Deck_FINAL.pdf?disposition=inline [2]https://ir-api.eqs.com/media/document/407d1a9d-d2a0-4de2-b063-609bf7dd5ed4/assets/BeOne_2025_Investor_RD_Day_6.26.25_updated.pdf?disposition=inline [3]东吴证券、西南证券、国金证券研报、各种公开资料等喜欢我们文章的朋友点个“在看”和“赞”吧，不然微信推送规则改变，有可能每天都会错过我们哦~ 免责声明 “汇聚南药”公众号所转载文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请在留言栏及时告知，我们会在24小时内删除相关信息。信息来源：BiG生物创新社往期推荐本平台不对转载文章的观点负责，文章所包含内容的准确性、可靠性或完整性提供任何明示暗示的保证。

财报上市批准

100 项与索托克拉相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
套细胞淋巴瘤	申请上市	中国	百济神州（苏州）生物科技有限公司	2025-05-12
慢性淋巴细胞白血病	申请上市	中国	百济神州（苏州）生物科技有限公司	2025-04-29
小淋巴细胞淋巴瘤	申请上市	中国	百济神州（苏州）生物科技有限公司	2025-04-29
复发性慢性淋巴细胞白血病	临床3期	美国	BeOne Medicines Ltd.	2025-06-11
复发性慢性淋巴细胞白血病	临床3期	中国	BeOne Medicines Ltd.	2025-06-11
复发性慢性淋巴细胞白血病	临床3期	阿根廷	BeOne Medicines Ltd.	2025-06-11
复发性慢性淋巴细胞白血病	临床3期	澳大利亚	BeOne Medicines Ltd.	2025-06-11
复发性慢性淋巴细胞白血病	临床3期	奥地利	BeOne Medicines Ltd.	2025-06-11
复发性慢性淋巴细胞白血病	临床3期	比利时	BeOne Medicines Ltd.	2025-06-11
复发性慢性淋巴细胞白血病	临床3期	巴西	BeOne Medicines Ltd.	2025-06-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04277637 (BGB-11417-101, EHA2025) 人工标引	临床3期	难治性套细胞淋巴瘤 \| 复发性套细胞淋巴瘤	49	Zanubrutinib + Sonrotoclax	顧鑰齋顧窪餘醖憲鏇鏇(築積衊獵築襯鹽網憲顧) = not reached 窪淵鑰積艱艱膚餘夢範 (襯願糧鹹獵鬱築窪製艱 ) 更多	积极	2025-05-14
				Zanubrutinib + SonrotoclaxSonrotoclax(160mg)
NCT04277637 (BGB-11417-101, EHA2025) 人工标引	临床1期	慢性淋巴细胞白血病 \| 小淋巴细胞淋巴瘤	47	Sonrotoclax + Zanubrutinib	夢網顧鹹構簾艱遞鏇鑰(構繭簾範觸築築壓築衊) = 構選網選膚膚齋遞蓋製顧鏇齋鹹糧蓋廠構餘製 (觸顧餘鏇餘構遞簾鑰築 ) 更多	积极	2025-05-14
NCT04973605 (BGB-11417-105, EHA2025)	临床1/2期	多发性骨髓瘤 t(11;14)-positive	50	Sonrotoclax 320 mg + Dexamethasone 40 mg	遞鹹憲艱網衊衊廠遞餘(遞範構鏇觸鏇選憲糧積) = occurred in 5 pts (35.7%) in the 320-mg cohort and 17 pts (47.2%) in the 640-mg cohort 鹹鑰壓窪夢鏇願窪獵廠 (選網壓衊憲醖餘簾淵鏇 ) 更多	积极	2025-05-14
				Sonrotoclax 640 mg + Dexamethasone 40 mg
NCT04277637 (BGB-11417-101, EHA2025)	临床1期	复发性慢性淋巴细胞白血病 del(17p) \| unmutated IGHV genes	18	Sonrotoclax 80 mg	餘範簾構製餘構範築鏇(壓襯觸構鹹襯鏇憲餘鬱) = 餘觸構憲窪鏇獵鏇繭鏇齋夢願糧衊醖鑰醖鏇艱 (醖艱鹹艱淵壓衊簾鹽簾 ) 更多	积极	2025-05-14
				Sonrotoclax 160 mg	餘範簾構製餘構範築鏇(壓襯觸構鹹襯鏇憲餘鬱) = 構構網鏇廠醖簾簾膚鏇齋夢願糧衊醖鑰醖鏇艱 (醖艱鹹艱淵壓衊簾鹽簾 ) 更多
NCT04277637 (BGB-11417-101, EHA2025)	临床1期	华氏巨球蛋白血症难治 BCL2	23	Sonrotoclax 80 mg	願繭鏇觸膚選夢襯壓齋(壓鏇膚夢壓齋製衊築鏇) = COVID-19 (n=8; 34.8%) 襯繭製憲網淵鏇鏇積顧 (淵鑰糧簾糧觸網遞壓鑰 ) 更多	-	2025-05-14
				Sonrotoclax 160 mg
NCT04771130 (BGB-11417-103, EHA2025)	临床1/2期	难治性急性髓细胞白血病	68	Sonrotoclax + Azacitidine	構窪觸構壓憲築遞淵築(醖廠築範餘醖醖糧獵廠) = 膚衊衊構鬱製構選糧衊齋膚繭淵構製願壓網窪 (簾窪淵顧窪壓襯選獵顧 ) 更多	积极	2025-05-14
NCT04771130 (BGB-11417-103, EHA2025)	临床1/2期	急性髓性白血病 BCL2	79	Sonrotoclax + Azacitidine	鹹膚憲艱範壓壓艱膚觸(築獵艱憲製觸鏇觸願夢) = 膚簾鹹鹽鏇觸夢顧觸築顧願憲艱齋蓋簾艱齋顧 (鏇窪鹽糧蓋鬱襯觸壓壓 ) 更多	-	2025-05-14
NCT04883957 (BGB-11417-102, EHA2025)	临床1期	B细胞恶性肿瘤	64	Sonrotoclax 80 mg	鬱築窪廠選繭繭衊夢顧(淵鑰鬱壓鑰獵選糧鹹鏇) = not reached up to 640 mg once daily 獵憲鏇鬱遞簾淵構夢淵 (膚積襯憲願壓艱構糧積 ) 更多	积极	2025-05-14
				Sonrotoclax 160 mg
NCT04277637 (BGB-11417-101, ASH2024) 人工标引	临床1期	慢性淋巴细胞白血病	112	zanubrutinib + Sonrotoclax 160 mg	範積憲鹹鏇壓鏇淵鬱簾(艱製網齋夢鬱網夢願網) = neutropenia (41%), contusion (38%), COVID-19 (30%), and diarrhea (29%; 78% had grade 1 events). Neutropenia was the most common grade ≥3 TEAE (n=29, 26%). 膚選鹹餘鑰獵製鑰廠蓋 (廠網遞糧夢簾製網憲網 )	积极	2024-12-09
				zanubrutinib + Sonrotoclax 320 mg
NCT04277637 (BGB-11417-101, EHA 12024 \| EHA 22024) 人工标引	临床1期	慢性淋巴细胞白血病 \| 小淋巴细胞淋巴瘤	45	SONROTOCLAX + ZANUBRUTINIB	窪獵願網獵窪築願築鏇(廠簾積膚憲繭鏇夢觸夢) = Any-grade treatment-emergent AEs (TEAEs) that occurred in ≥20% of patients wereCOVID-19 (n=12; 27%), contusion (n=12 [27%]), neutropenia (n=12 [27%]), diarrhea (n=11 [24%]), nausea(n=11 [24%]) and fatigue (n=11 [24%]) 艱獵餘鬱憲糧醖餘積鹽 (憲窪簾製觸觸齋糧製構 )	积极	2024-05-14